The 2026 edition of ICD-10-CM E50.1 became effective on October 1, 2025
Stop using Saxenda and get medical help right away if you have any symptoms of a serious allergic reaction including swelling of your face, lips, tongue, or throat, fainting or feeling dizzy, very rapid heartbeat, problems breathing or swallowing, or severe rash or itching depression or thoughts of suicide

Additional Caution May Be Appropriate If You: Have highly sensitive or reactive skin Are prone to allergies or cosmetic skin irritation Have rosacea-prone skin Are currently utilizing strong exfoliating acids or active skincare ingredients Have a compromised, damaged, or irritated skin barrier Avoid Cosmetic Application To: Broken skin Open wounds Severely irritated areas Areas experiencing active irritation or heightened sensitivity Cosmetic Formulation Considerations Lower introductory concentrations are commonly preferred when beginning new cosmetic peptide formulations Patch testing is recommended before larger cosmetic application areas Gradual introduction into cosmetic skincare routines is generally preferred Formulation compatibility with other active skincare ingredients should be considered If uncertain whether a cosmetic peptide formulation is suitable for a specific skincare routine, consultation with a qualified skincare professional may be considered prior to cosmetic use

ACL fibroblasts, the cells responsible for producing and maintaining the ECM, respond to mechanical loading through mechanotransduction pathways